Relapsed or refractory DLBCL: reassessment and the next treatment decision

A new mass or suspicious PET uptake after DLBCL treatment needs prompt reassessment, but a scan alone should not declare every treatment ineffective. Confirm active lymphoma, establish whether the histology is unchanged and determine whether the situation is primary refractory disease, early relapse or later relapse. Those distinctions influence the sequence of CAR T cells, salvage therapy with autologous transplantation, bispecific antibodies and other medicines. [S1,S3]

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Infection, inflammation, scar and another malignancy can cause new abnormalities. Someone with an earlier indolent component may not have identical histology at recurrence. A representative biopsy can prevent a high-intensity treatment decision based on the wrong diagnosis and supply information relevant to later targets. [S2]
STARGLO compared glofitamab plus GemOx with rituximab plus GemOx in previously treated, transplant-ineligible relapsed or refractory DLBCL. Later follow-up provides additional evidence. [S25,S26] It was not a direct comparison with CAR T cells and should not be generalized to every untreated or transplant-eligible patient.
The plan should state when response will be checked, what supports continuation and what would prompt a change. For patients unlikely to obtain durable control, pain, breathing, sleep and family priorities still deserve focused care. Palliative care can accompany anticancer treatment rather than requiring its automatic cessation.

Quick answer

Full guide

A team familiar with both lymphoma salvage treatment and cellular therapy can integrate the choices. Respiratory, bowel or neurological compromise needs attention at the same time. Emergency care should not wait for a perfect records package, although an accurate treatment history is essential for the formal next-line decision.

Confirm recurrence with appropriate tissue when feasible

Infection, inflammation, scar and another malignancy can cause new abnormalities. Someone with an earlier indolent component may not have identical histology at recurrence. A representative biopsy can prevent a high-intensity treatment decision based on the wrong diagnosis and supply information relevant to later targets. [S2]

The team selects a useful, safely accessible site. If the clinical situation is urgent, ask how diagnostic sampling and stabilization will be balanced. Do not independently use steroids or anticancer medicines to shrink the lesion before sampling. Any interim treatment should be coordinated and recorded with exact dates.

Build an accurate treatment and relapse timeline

Record diagnosis, each regimen's start and end, best response, last dose and the date relapse was established. Saying that six chemotherapy visits occurred last year does not identify lines of therapy or the interval that affects indications. A delay for infection is different from a switch because of progression.

Definitions of refractory disease can vary between clinical and research documents. Early and later relapse should be assigned using the actual dates and the relevant definition. Some CAR T indications explicitly use relapse within 12 months of first-line therapy, so approximate recollection is insufficient. [S5]

Seek early CAR T assessment when the setting supports it

Some patients with primary refractory or early relapsed disease can be evaluated in the second-line setting rather than exhausting every conventional salvage regimen first. Assessment includes pathology, timing, organ function, infection, fitness and support. The US lisocabtagene maraleucel indication includes defined refractory, early-relapse and other circumstances; China eligibility requires separate verification. [S5]

An early referral establishes feasibility, not a promise of infusion. Ask about collection, bridging, the effect of clinical deterioration and alternatives if eligibility is not met. A local clinician must remain responsible for active disease while the patient waits for a specialist appointment or manufacturing slot.

Treat the manufacturing interval as part of care

Some patients need medicines or localized radiation between collection and product readiness. Bridging is selected according to disease growth, previous exposure, collection timing and organ reserve. Its purpose is to help the person reach the next phase safely, not to provide an opportunity for self-directed additional treatment. [S11]

Infection or worsening kidney or liver function can postpone lymphodepletion and infusion. Review manufacturing progress, disease control and fitness together. If the original plan becomes infeasible, discuss alternatives and financial arrangements promptly. Cross-border planning must include this uncertain interval rather than an arrival date for infusion alone.

Understand the later-relapse transplant pathway

Selected fit patients with a later relapse may receive salvage treatment to establish sensitivity, followed by high-dose treatment and autologous stem cell transplantation when appropriate. Regimens such as R-ICE, R-DHAP or alternatives are selected with previous exposure and organ function in mind. Their names do not create a simple ranking of strength. [S1,S13]

Collection, infection control, heart and lung fitness and support all matter before transplantation. The response to salvage therapy can change the decision. Ask in advance what happens if the response is inadequate: CAR T assessment, a bispecific or a study may be considered rather than repeating cycles without a defined objective.

Do not equate transplant ineligibility with ineligibility for all active treatment

A patient unable to tolerate high-dose conditioning may still be eligible for selected cellular therapy, bispecific antibodies or other combinations. Ask why transplantation is unsuitable: frailty, organ function, infection, disease response or a temporary support problem. Some limitations can improve, while others genuinely change the goal.

Epcoritamab and glofitamab have specified US later-line large B-cell lymphoma indications and require product-specific safety arrangements. [S6,S7] They are not risk-free substitutes for everyone who cannot undergo transplantation. Early observation, later doses, infection prevention and access after returning home must be feasible.

Match newer combinations to the population actually studied

STARGLO compared glofitamab plus GemOx with rituximab plus GemOx in previously treated, transplant-ineligible relapsed or refractory DLBCL. Later follow-up provides additional evidence. [S25,S26] It was not a direct comparison with CAR T cells and should not be generalized to every untreated or transplant-eligible patient.

In 2025, the FDA approved brentuximab vedotin with lenalidomide and rituximab for specified adults after at least two lines who were ineligible for autologous transplantation or CAR T cells. [S29] That does not establish China access. For any combination, review the indication, earlier targets and blood-count or neurological toxicity alongside the evidence.

Reassess the disease after CAR T relapse

Suspicious findings after cell therapy still require interpretation according to timing, imaging, symptoms and possible biopsy. Confirmed relapse leads to review of current targets, earlier antibodies, blood-count recovery, infection and organ status. Merely choosing another similarly named CAR T product does not necessarily address antigen change or resistance. [S1,S11]

Medicines, bispecific antibodies, local radiation, trials or selected transplant-related approaches require specialist assessment. Avoid both a guarantee that another infusion will work and an assumption that no further care is useful. The exact cell product and complete post-infusion record are particularly important for a second opinion.

Recognize disease features that change the urgent sequence

Persistent headache, visual change, seizure, weakness or altered thinking can require evaluation for central nervous system disease. That setting may need different systemic or local treatment considerations from ordinary extranodal relapse. Kidney function and overall disease control remain part of the decision. [S3]

Severe back pain with bladder symptoms, respiratory difficulty, major bleeding or acute abdominal symptoms should be assessed locally without waiting for a China consultation. Send records of emergency procedures, steroids, antibiotics and transfusions to the later center. These interventions can affect what is safe next.

Assess accumulated toxicity alongside disease control

After several lines, marrow and immune reserve may be reduced, while neuropathy and nutritional problems accumulate. CAR T cells and bispecifics require attention to cytokine release syndrome and neurological toxicity. Removal of certain US CAR T REMS requirements did not remove monitoring needs or long-term safety concerns. [S19,S23]

Fever of 38°C or above, chills, symptoms of low blood pressure, breathlessness or confusion needs urgent contact and emergency assessment when directed. [S8] Infection, immune reactions and lymphoma can overlap. Patients should not decide the cause at home before choosing medicines. Establish transport and emergency access beforehand.

Consider a trial while maintaining present care

A study may be relevant when usual options are limited or its question fits the pathology and treatment history. Confirm recruitment at the actual site, eligibility, washout rules, biopsies and cost responsibilities. A registry entry does not establish an available slot or acceptance of international participants. [S16,S17]

Screening should run alongside a plan for current disease. If waiting is unsafe, the local and research teams should agree interim management. Do not stop necessary infection treatment or other medicines to preserve an unconfirmed trial opportunity. Any change affecting eligibility must be clinically coordinated.

Make a China referral specific and financially complete

Submit repeat pathology, all scans, every treatment line and best response, cell-product records and current laboratory results. Ask which pathway can be assessed and what remains missing. Clarify whether the visit is for consultation, collection, admission or research screening. Rapidly progressing disease warrants remote confirmation that timely assessment is possible before travel.

In Chinese yuan, separate reassessment, salvage or bridging, collection and manufacture, admission, infection support, intensive care and follow-up. No verified individual quotation is available here. Cancellation, delay and readmission responsibilities need written clarification. Include the caregiver and home-country tests so that funding covers observation as well as the main treatment. [S10]

Define the next reassessment point

The plan should state when response will be checked, what supports continuation and what would prompt a change. For patients unlikely to obtain durable control, pain, breathing, sleep and family priorities still deserve focused care. Palliative care can accompany anticancer treatment rather than requiring its automatic cessation.

Before returning home, obtain the response summary, medication and infection plan, blood-count schedule and urgent contacts. [S12] Several teams may be involved, but the patient should not be the only messenger between them. Clear responsibility reduces gaps at a time when continuity is particularly important.